XML 38 R21.htm IDEA: XBRL DOCUMENT
v3.25.4

Subsequent Events | 12 Months Ended
--- | ---
Sep. 30, 2025
Subsequent Events [Abstract] |
SUBSEQUENT EVENTS | 13. SUBSEQUENT EVENTS On October 20, 2025, Citius Pharmaceuticals, Inc. entered into a securities purchase agreement with a certain institutional investor for the issuance and sale, in a registered direct offering by the Company , of 1,460,000 shares of the Company’s common stock, par value $0.001 per share , and pre-funded warrants to purchase up to 2,513,510 shares of common stock at an offering price of $1.51 and $1.5099, respectively. The Company also issued to the investor warrants to purchase up to 3,973,510 shares of common stock. The offering closed on October 21, 2025. Gross proceeds were approximately $6.0 million, before deducting placement agent fees and other expenses. On December 8, 2025, Citius Oncology entered into a securities purchase agreement with a certain institutional investor in a registered direct offering for the purchase and sale of 1,284,404 shares of our common stock at an offering price of $1.09 per share of common stock. In a concurrent private placement, the Company also agreed to sell such institutional investor warrants to purchase up to 1,284,404 shares of common stock, with an exercise price of $1.09 per share of our common stock, which are exercisable upon the requisite stockholder approval, and have a term of five years from the date of the stockholder approval. The aggregate gross proceeds to the Company from the offering were approximately $18.0 million. Net proceeds were approximately $15.2 million, after deducting placement agent fees and other offering expenses payable by the Company. On December 8, 2025, Citius Oncology also entered into a securities purchase agreement with such institutional investor to issue in a concurrent private placement pre-funded warrants to purchase up to 15,229,358 shares of common stock and 15,229,358 warrants, at a combined price of $1.0899 per pre-funded warrant and accompanying warrant. The pre-funded warrants are exercisable immediately, at an exercise price of $0.0001 per share, and will remain valid and exercisable until all the pre-funded warrants are exercised in full. In connection with the offering, Citius Oncology agreed to pay the placement agent a cash fee of 7.0% of the aggregate gross proceeds Citius Oncology received in the offering. In addition, the Company granted warrants to the placement agent, or its designees, to purchase up to 1,155,963 shares of common stock. The terms of the placement agent warrants are substantially the same as the terms of the warrants, except that the exercise price is $1.3625 per share and expire five years from the commencement of sales in the offering.

X
- References No definition available. + Details
Name: | us-gaap_SubsequentEventsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContent Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details
Name: | us-gaap_SubsequentEventsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration